Trial Details

COMPLETED
Basic Information
Clinical ID c3508
Identifier NCT01940848
Trial Title Efficacy/Safety Study to Confirm Iberogast's Efficacy in Patients With Irritable Bowel Syndrome Diagnosed on ROME III Criteria Compared to Placebo
Trial URL Visit Original Page
Study Information
Study Results

NO

Conditions Irritable Bowel Syndrome
Interventions DRUG: STW5 (Iberogast, BAY98-7411)|DRUG: Placebo
Participant Information
Sponsor Bayer
City Baden-Wurttemberg
Country/Region Germany
Enrollment Criteria
Sex Requirement ALL
Age Requirement ADULT, OLDER_ADULT
Study Design
Study Type INTERVENTIONAL
Phase PHASE3
Time Information
Start Date 2013-10-11
Primary Completion Date 2017-10-25
Completion Date 2017-10-25